What is the recommended way to discontinue latuda (lurasidone) after 10 months of use?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Discontinuing Latuda After 10 Months: Gradual Taper Over 1+ Month

After 10 months of Latuda (lurasidone) use, discontinue gradually over a period of at least 1 month to minimize withdrawal effects, using dose reductions of approximately 10% of the current dose every 1-2 weeks, with close monitoring for withdrawal symptoms and relapse.

Why Gradual Tapering is Essential

Antipsychotics like Latuda require gradual withdrawal to prevent serious discontinuation effects. Abrupt discontinuation can cause dyskinesias, parkinsonian symptoms, dystonias, and in rare cases, neuroleptic malignant syndrome 1. The FDA label for Latuda does not provide specific tapering guidance, but general antipsychotic deprescribing principles apply 2.

Recommended Tapering Schedule

Standard Approach

  • Reduce by 10% of the current dose every 1-2 weeks
  • Total taper duration: minimum 1 month, often extending to 2-3 months 1
  • For patients on higher doses or with prior withdrawal difficulties, consider slower tapers extending several months

Practical Example

If you're taking 80mg daily:

  • Week 1-2: Reduce to 72mg (10% reduction)
  • Week 3-4: Reduce to 65mg (10% of 72mg)
  • Week 5-6: Reduce to 58mg (10% of 65mg)
  • Continue this pattern until discontinuation

Monitoring Requirements

Monitor every 1-2 weeks during the taper and for 2-3 months after complete discontinuation 3, 4. This is the highest-risk period for both withdrawal symptoms and relapse.

What to Watch For:

Withdrawal symptoms:

  • Movement disorders (dyskinesias, akathisia, dystonia)
  • Parkinsonian symptoms
  • Insomnia and anxiety
  • Nausea
  • Agitation or irritability

Relapse indicators:

  • Return of original psychiatric symptoms
  • New psychotic symptoms
  • Mood destabilization (if used for bipolar depression)

Critical Distinction: Withdrawal vs. Relapse

This is often the most challenging clinical judgment. Withdrawal symptoms typically:

  • Appear within days to 2 weeks of dose reduction
  • Are often physical/neurological in nature
  • May improve with slowing or pausing the taper

Relapse symptoms typically:

  • Emerge more gradually (weeks)
  • Match the original psychiatric presentation
  • Require consideration of resuming medication

When to Pause or Reverse the Taper

If significant withdrawal symptoms emerge:

  • Pause the taper at the current dose for 2-4 weeks
  • If symptoms persist or worsen, increase back to the previous tolerated dose
  • Once stabilized, resume tapering at a slower rate (5% reductions every 2-4 weeks)

If relapse occurs:

  • Return to the last effective dose
  • Reassess the appropriateness of discontinuation
  • Consider whether this is the right time to stop

Special Considerations

For Bipolar Depression

If Latuda was used for bipolar depression, ensure mood stabilizers (lithium or valproate) remain optimized during and after the taper, as these provide ongoing mood protection 2.

Adjunctive Support During Tapering

While evidence is limited specifically for antipsychotic withdrawal, consider:

  • Maintaining regular sleep-wake cycles
  • Stress reduction techniques
  • Close clinical support and reassurance
  • Addressing any emerging anxiety or insomnia symptomatically if needed

Common Pitfalls to Avoid

  1. Never stop abruptly - This significantly increases risk of withdrawal dyskinesias and other movement disorders 1

  2. Don't rush the taper - Faster tapers (over days to 1-2 weeks) substantially increase withdrawal symptom severity

  3. Don't abandon the patient - Discontinuing monitoring after stopping the medication misses the critical 2-3 month window when relapse risk is highest 3, 5

  4. Don't confuse withdrawal with relapse - This leads to either unnecessary medication resumption or dangerous continuation of tapering during actual relapse

Patient Education Points

Inform patients that:

  • Some transient discomfort during tapering is common but manageable
  • The taper can be slowed or paused at any time based on symptoms
  • Close follow-up is essential for safety
  • Not everyone experiences withdrawal symptoms
  • The goal is safe discontinuation while minimizing both withdrawal effects and relapse risk

References

1
Guideline

polypharmacy management in older patients.

Mayo Clinic Proceedings, 2021

5
Guideline

practice parameter on the use of psychotropic medication in children and adolescents.

Journal of the American Academy of Child and Adolescent Psychiatry, 2009

Related Questions

Can lurasidone (Latuda) cause yellow, loose stools?
Can stopping Latuda (lurasidone) cause overstimulation?
I have been off Latuda (lurasidone) 40 mg daily for 17 days; when is the mental fogginess expected to resolve?
I have been off lurasidone (Latuda) for 22 days after taking 40 mg daily for 10 months; when can I expect to feel better?
I stopped lurasidone (Latuda) 40 mg daily after ten months of use; 22 days later I still have brain fog—what steps should I take?
What are the common signs and symptoms of perimenopause?
What Vyvanse (lisdexamfetamine) dose is equivalent to an adult patient taking Adderall (amphetamine) immediate‑release 30 mg twice daily, given the FDA‑approved maximum daily dose of Adderall IR is 40 mg?
I am a 6‑ft‑5‑in, 318‑lb Black male with probable mixed connective tissue disease, modestly elevated creatinine, normal estimated glomerular filtration rate, mildly elevated creatine kinase, low erythrocyte sedimentation rate and C‑reactive protein, positive speckled antinuclear antibody with high anti‑RNP, negative anti‑Jo‑1, normal electromyography, and a cardiac work‑up showing only a transient abnormal ECG but normal troponin trend and a pending stress test; what specific type of inflammatory myopathy (myositis) am I most likely to have, what is the expected prognosis, and should I continue regular physical and occupational therapy?
What is the differential diagnosis for new‑onset, sporadic unilateral eyelid ptosis in an adult?
Can I continue Vyvanse (lisdexamfetamine) 40 mg, lamotrigine titration, hydroxyzine 25 mg as needed, and venlafaxine (Effexor) at the current dose, while switching to propranolol for anxiety and adding quetiapine (Seroquel) for sleep?
What is the preferred first‑line antihypertensive medication for a patient with hypertension and kidney stones?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.